Possidente Luciana, Landriscina Matteo, Patitucci Giuseppe, Borgia Ludovica, Lalinga Vittoria, Vita Giulia
Laboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Laboratory of Preclinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Med Oncol. 2017 May;34(5):76. doi: 10.1007/s12032-017-0936-z. Epub 2017 Mar 31.
Lung adenocarcinomas are characterized by a variety of genetic and epigenetic changes that lead to activation of specific signaling pathways. This allowed the classification of lung adenocarcinomas according to genetic alterations and the clinical development of novel anticancer agents that affect the activity of specific oncoproteins. In such a context, chromosomal rearrangements that cause constitutive activation of ALK gene define a category of lung adenocarcinomas that is amenable to targeted therapy with ALK inhibitors. Thus, a major issue of current research is to define the morphological and immunophenotypic features of lung ALK-rearranged adenocarcinomas to improve the selection of tumors suitable for molecular genotyping. ALK status was determined, by immunohistochemistry and fluorescence in situ hybridization, in 94 surgically resected lung adenocarcinomas and correlated with histomorphological parameters. Indeed, ALK rearrangement was observed in 10/94 (11%) lung adenocarcinomas and enriched in tumors with a predominant mucinous (46%; p < 0.05) and solid (29%; p < 0.05) pattern. By contrast, it was lacking or sporadically observed in lung adenocarcinomas with predominant acinar, papillary or lepidic pattern. Moreover, the presence of signet-ring cells was predominantly observed in ALK-rearranged tumors (47%; p < 0.05). These data suggest that ALK rearrangement is associated with specific and distinct clinical-pathological characters compared to other genotypes. Thus, the knowledge of these characteristics can improve the diagnostic accuracy and lead to a better understanding of the behavior of ALK-rearranged NSCLC.
肺腺癌具有多种导致特定信号通路激活的基因和表观遗传变化。这使得肺腺癌能够根据基因改变进行分类,并推动了影响特定癌蛋白活性的新型抗癌药物的临床研发。在这种背景下,导致ALK基因组成性激活的染色体重排定义了一类可采用ALK抑制剂进行靶向治疗的肺腺癌。因此,当前研究的一个主要问题是明确肺ALK重排腺癌的形态学和免疫表型特征,以改善适合分子基因分型的肿瘤的选择。通过免疫组织化学和荧光原位杂交确定了94例手术切除的肺腺癌中的ALK状态,并将其与组织形态学参数相关联。实际上,在94例肺腺癌中有10例(11%)观察到ALK重排,且在以黏液为主(46%;p<0.05)和实性为主(29%;p<0.05)的肿瘤中更为富集。相比之下,在以腺泡、乳头或贴壁为主型的肺腺癌中未观察到或仅偶尔观察到ALK重排。此外,印戒细胞的存在主要见于ALK重排的肿瘤(47%;p<0.05)。这些数据表明,与其他基因型相比,ALK重排与特定且独特的临床病理特征相关。因此,了解这些特征可以提高诊断准确性,并有助于更好地理解ALK重排的非小细胞肺癌的行为。